Product logins

Find logins to all Clarivate products below.


Post-Traumatic Stress Disorder – Epidemiology – Epidemiology – Post-Traumatic Stress Disorder – Mature Markets

Clarivate Epidemiology’s coverage of post-traumatic stress disorder comprises epidemiological estimates of key patient populations across seven countries worldwide. We report the prevalence of post-traumatic stress disorder for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s post-traumatic stress disorder forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of post-traumatic stress disorder over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts over two patient populations, as follows:

  • PTSD total 12-months prevalence.
  • PTSD total lifetime prevalence

Note: coverage may vary by country.

Related Market Assessment Reports

Report
Chronic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Back Pain (US)
Approximately 30 million people in the United States have chronic back pain (CBP). Treatment of CBP poses a challenge to physicians owing to the heterogeneity of pain pathophysiology and the…
Report
Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.)…
Report
Post-Traumatic Stress Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Post-Traumatic Stress Disorder (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
Report
Axial Spondyloarthritis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: TNF-alpha inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira, Johnson & Johnson…
Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early…